CURRICULUM VITAE

Bonnie L. Miller, RN, CCRC9300 Candlewood Dr

Oklahoma City, OK 73112BonnieMiller.RN@gmail.com

405-777-9343

Education:Eastern Florida State College, Cocoa, FL- Associate Degree in Nursing 1999 - 2000

Adventist University of Health Sciences- Licensed Practical Nurse 1997 - 1998

Professional Experience:

Clinical Research Specialist, CCRC 9/2014 - presentINTEGRIS Health- Nazih Zuhdi Transplant InstituteOklahoma City, OK

Staff RN 7/2014 – 08/2014

Select Specialty Hospital-LTACOklahoma City, OK

Sr. CCRCOklahoma Heart Hospital Research Foundation 6/2013 – 5/2014Oklahoma City, OK

CRC 1/2013 - 4/2013Clinforce, LLC Durham, NC

CRC, Staff RN, Infusion Therapy Nurse 4/2004 – 1/2013Internal Medicine Associates of Greenville

Circulator, Scrub, PACU, and ER Nurse 4/2001 – 4/2004Cannon Memorial Hospital

Staff RN- Neuroscience 7/2000 – 4/2001Greenville Memorial HospitalGreenville, SC

License and Certifications:

Registered Nurse- Oklahoma 06/2013 - 9/2016CCRC- Academy of Clinical Research Professionals 04/2014 - 5/2016ACLS and BLS - American Heart Association 03/2014 – 3/2016American Nurses Association 11/06/14 - /2016

Hospital Affiliations:INTEGRIS Health 09/2014

1Bonnie Miller, RN, CCRC

Clinical Research Studies:

SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant.

SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT).

HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.

ROADMAP is Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management.

Collection of Plasma Samples From Individuals Initiating Therapy With Entecavir or Tenofovir for Chronic Hepatitis B Virus Infection for the Clinical Evaluation of the Aptima HBV Quant Assay.

Time Perspective: Prospective for the majority of patients who are enrolled at the time they begin Nulojix (belatacept) treatment. Retrospective for any patients receiving Nulojix (belatacept) prior to enrollment into ENLiST Registry.

A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC).

Evaluation of the safety and effectiveness of the HeartMate III LVAS by demonstrating non-inferiority to the HM II LVAS (HM II) when used for the treatment of advanced, refractory, left ventricular heart failure.

REALM Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated With Nucleoside/Nucleotide Monotherapy for Patients With Chronic HBV Infection.

The Randomized Evaluation of VAD InterVEntion Before Inotropic Therapy (REVIVE-IT).

INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a FDA approved Mechanical Circulatory Support Device.

A Phase II Clinical Study of the Safety and Performance of the Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms.

ABSORB III Prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS).

The Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease.

COSMIC Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With HF and Left Ventricular Systolic Dysfunction.

A Multi-Center Single Arm Observational Registry of the Cardiogenesis Holmium: YAG Laser System Transmyocardial Revascularization for Angina Reduction.

EUCLID Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease.

2Bonnie Miller, RN, CCRC

RELAX Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure.

ABLATE Multi-Center Single Arm Observational Registry of the Cardiogenesis Holmium: YAG Laser System Transmyocardial Revascularization for Angina Reduction.

SYMPLICITY HTN 4 Renal Denervation in Patients with Uncontrolled Hypertension.

INOVATE Randomized Study to Establish the Safety and Efficacy of CardioFit® for the Treatment of Subjects With Heart Failure and Left Ventricular Dysfunction.

AVERT Prospective Randomized, Study to Evaluation the Safety and Efficacy of the Osprey Medical System in Subjects with Chronic Kidney Disease.

PARACHUTE Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System.

PRESERV Prospective Randomized Evaluation to study the Effects of Reduced Contrast Media on the Vitality of the Kidney.

RIBOCOR Randomized, Double-Blind, Placebo-Controlled Study To Evaluate D-Ribose For The Treatment Of Congestive Heart Failure.

EVITA Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adolescent Smokers.

SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy.

CANOPY Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy.

LAPTOP Prospective Randomized, Study to Evaluation the Safety and Efficacy of the left atrial pressure measurements in Subjects with Heart Failure.

SAVOR Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes.

HOPE4HF Prospective, Randomized, Study Describing the Safety and Efficacy of the Neo system in HF patients.

LEADER Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events.

CANTOS Substudy of the CANTOS Trial (Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP.

TAKEDA Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment.

ALTITUDE Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality.

3Bonnie Miller, RN, CCRC

AIM-HIGH Plaque Inflammation and Dysfunctional HDL Cholesterol in Participants Receiving Niacin and Statins.

IDAU A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared to Pre-prandial Injectable Insulin in Insulin-Naive Patients With Type 2 Diabetes Mellitus.

VAL-DICTATE Multicenter, randomized, active controlled, parallel group trial in 291 hypertensive patients whose BP was uncontrolled on diuretic monotherapy.

JUPITER Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of LDL Cholesterol & Elevated Levels of C-Reactive Protein.

ACCOMPLISH Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension.

4Bonnie Miller, RN, CCRC